Taxotere Wins FDA Approval for Advanced Gastric Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 4
Volume 15
Issue 4

The FDA has approved the use of Taxotere (docetaxel, Sanofi-Aventis) in combination with cisplatin and fluorouracil (5-FU) for the treatment of advanced gastric cancer, including cancer of the gastroesophageal junction, in patients who have not received prior chemotherapy for their advanced disease.

 

ROCKVILLE, Maryland-The FDA has approved the use of Taxotere (docetaxel, Sanofi-Aventis) in combination with cisplatin and fluorouracil (5-FU) for the treatment of advanced gastric cancer, including cancer of the gastroesophageal junction, in patients who have not received prior chemotherapy for their advanced disease. According to the company, Taxotere is the first drug approved for advanced stomach cancer in more than a decade that has demonstrated a survival advantage.

FDA granted approval on the basis of data from TAX 325, a randomized, international phase III clinical trial and the largest study conducted in previously untreated advanced gastric cancer patients. Taxotere was initially approved in 1996 for treating advanced breast cancer and later for use as adjuvant therapy of breast cancer and in patients with advanced non-small-cell lung cancer and advanced prostate cancer.

TAX 325 randomized 445 patients to receive Taxotere plus cisplatin/5-FU or the standard treatment of cisplatin/5-FU. Median follow-up was 23 months. Time to tumor progression, the primary endpoint, was 5.6 months in the Taxotere arm vs 3.7 months in patients receiving the standard treatment (P = .0004), a hazard ratio of 1.47. The Taxotere group had an overall survival of 9.2 months vs 8.6 months for the standard treatment arm (P ≤ .02), a hazard ratio of 1.29.

In the TAX 325 study, 81.4% of the Taxotere-treated patients had at least one grade 3-4 adverse event vs 76.4% in the standard treatment arm. Neutropenia was the most common grade 3-4 event in the Taxotere group. (The protocol did not allow primary prophylaxis with G-CSF.) The most common side effects of all grades in the Taxotere arm were anemia, neutropenia, diarrhea, and nausea, and, in the control arm, anemia, neutropenia, and nausea and vomiting.

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content